Peptomyc is a company focused on the development of a new generation of cell penetrating peptides

Startup

SOBRE PEPTOMYC

      
Peptomyc is a company focused on the development of a new generation of cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.
Currently, cancer incidence in the world exceeds 14 million cases per year and results in 8 million deaths annually. Moreover, such numbers are forecast to rise by 75% over the next 20 years (World Cancer Report. International Agency for Research on Cancer 2014). At the moment, standard therapies include surgery, radiotherapy, chemotherapy, and, in a restricted subset of cancers, precision medicine. Unfortunately, very often these therapies fail, due to the development of resistance.

Peptomyc has adopted a different strategy based on the inhibition of the oncoprotein Myc, which is found deregulated in the majority of human cancers. Myc holds a non-redundant function in cancer around which tumors cannot evolve, hence targeting Myc is the most promising therapeutic opportunity to date. Although Myc plays a central role in cancer there is currently no Myc inhibitor in the market.
    

SECTORES - INDUSTRIA

UBICACIONES

COMPARTIR PERFIL

Este perfil tiene una gran apariencia, ¿quieres compatirlo con todos?
PRINCIPIANTE
AVANZADO
PROFESIONAL

Esta web usa cookies para que podamos entender cómo se utiliza el sitio. Si sigues navegando asumiremos que te parece bien. Si quieres utilizar este sitio sin cookies o si quieres saber más, puedes hacerlo aquí .